Virus-derived particles target blood cancer

Ottawa researchers have developed an experimental therapy that can kill human blood cancer cells in the laboratory and eradicate the disease in mice

2013-08-13

(Press-News.org) Ottawa researchers have developed unique virus-derived particles that can kill human blood cancer cells in the laboratory and eradicate the disease in mice with few side effects. The study is published in Blood Cancer Journal by co-senior authors Drs. David Conrad and John Bell of the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa (uOttawa).

While Dr. Bell and his colleagues have been investigating replicating viruses for the treatment of solid cancers for many years, with very promising results, this is the first major success they have had treating blood cancer (leukemia). It is also the first success they have had using a non-replicating virus-derived particle as opposed to a replicating virus.

"Our research indicated that a replicating virus might not be the safest or most effective approach for treating leukemia, so we decided to investigate whether we could make virus-derived particles that no longer replicate but still kill cancer," said Dr. Conrad, a hematologist conducting research in the Blood and Marrow Transplant Program at The Ottawa Hospital, and currently completing his PhD at OHRI and uOttawa in the Department of Cellular and Molecular Medicine. "We were delighted to see that this novel therapy was very safe at high doses, and worked extremely well in our laboratory leukemia models. We hope to test this in patients in the near future."

The researchers used a specific method and dose of UV light to transform regular replicating viruses into unique particles that could no longer replicate and spread, but could still enter cancer cells efficiently, kill them and stimulate a strong immune response against the cancer. These particles were able to kill multiple forms of leukemia in the laboratory, including samples taken from local patients who had failed all other therapies. Normal blood cells were not affected. This novel treatment was also successful in mouse models of leukemia. In fact, 80 per cent of the mice that received the therapy had markedly prolonged survival and 60 per cent were eventually cured, while all of the untreated mice died of their leukemia within 20 days.

"Leukemia is a devastating disease that can be very difficult to treat, and new therapies are urgently needed," said Dr. Conrad. "While we're still at the early stages of this research, I think this therapy holds a lot of promise because it appears to have a potent, long-lasting effect on leukemia without the debilitating side effects of many cancer therapies used in the clinic right now. We will likely see even better results once we optimize the dose in our preparations to advance this research into human clinical trials."

INFORMATION:

This research was funded by the Ontario Institute for Cancer Research, the Terry Fox Foundation, the Natural Sciences and Engineering Research Council of Canada, the Canadian Institutes of Health Research, Ottawa's Department of Medicine and The Ottawa Hospital Foundation.

Reference: Non-replicating rhabdovirus-derived particles (NRRPs) eradicate acute leukemia by direct cytolysis and induction of antitumor immunity. Batenchuk C, Le Boeuf F, Stubbert L, Falls T, Atkins HL, Bell JC, and Conrad DP. Blood Cancer J. 2013 Jul 12;3:e123. doi: 10.1038/bcj.2013.23. Corresponding author: Dr. David P Conrad. http://www.nature.com/bcj/journal/v3/n7/full/bcj201323a.html.

About the Ottawa Hospital Research Institute (OHRI)

The Ottawa Hospital Research Institute (OHRI) is the research arm of The Ottawa Hospital and is an affiliated institute of the University of Ottawa, closely associated with the university's Faculties of Medicine and Health Sciences. OHRI includes more than 1,700 scientists, clinical investigators, graduate students, postdoctoral fellows and staff conducting research to improve the understanding, prevention, diagnosis and treatment of human disease. http://www.ohri.ca

Media contact

Jennifer Ganton
Director, Communications and Public Relations, Ottawa Hospital Research Institute
613-798-5555 x 73325
613-614-5253 (cell)
jganton@ohri.ca

ELSE PRESS RELEASES FROM THIS DATE:

New strategy to disarm the dengue virus brings new hope for a universal dengue vaccine

2013-08-13

1. A new strategy that cripples the ability of the dengue virus to escape the host immune system has been discovered by A*STAR's Singapore Immunology Network (SIgN). This breakthrough strategy opens a door of hope to what may become the world's first universal dengue vaccine candidate that can give full protection from all four serotypes of the dreadful virus. This research done in collaboration with Singapore's Novartis Institute of Tropical Diseases (NITD) and Beijing Institute of Microbiology and Epidemiology is published in the Plos Pathogens journal, and is also supported ...

Enhancer RNAs may open new avenues for gene therapy

2013-08-13

A study investigating the function of the recently discovered enhancer RNA molecules may open new avenues for gene therapy. According to the study researchers, altering the production and function of these molecules could affect the expression of genes and, in consequence, possibly also the progression of various diseases. Published in the prestigious Molecular Cell on 8 August, the study was carried out in collaboration between the University of California, San Diego and the University of Eastern Finland. Besides promoters located in the beginning of genes, gene expression ...

Therapeutic changes in glioma mice after transplantation of neural stem cells

2013-08-13

Neural stem cells transplanted into tumor-bearing rats can hinder tumor cell growth and prolife-ration; however, the mechanism remains unclear. Abnormal activation of the Ras/Raf/Mek/Erk signaling cascade plays an important role in glioma. Inhibition of this aberrant activity could effectively hinder glioma cell proliferation and promote cell apoptosis. To investigate the mechanism of glioblastoma treatment by neural stem cell trans-plantation with respect to the Ras/Raf/Mek/Erk pathway, Hua Li and team from the 476 Hospital of Chinese PLA observed Raf-1, Erk and Bcl-2 ...

A 3-D digital visualization model of cervical nerves in a healthy person

2013-08-13

High-resolution multilayer X-ray computer tomography and 3.0T superconducting magnetic resonance myelography are known to obtain a more complete and continuous two-dimensional original data. Three-dimensional reconstruction nerve models are classically obtained from two-dimensional images of "visible human" frozen sections. However, because of the flexibility of nerve tissues and small color differences compared with surrounding tissues, the integrity and validity of nerve tissues can be impaired during milling. Jiaming Fu and colleagues from the 98 Hospital of Chinese ...

Poly(lactic-co-glycolic acid) conduit is suitable for repair of injured sciatic nerve

2013-08-13

The conventional method for repair of peripheral nerve injury is autogenous nerve grafting, but sources of autogenous nerve are limited. Furthermore, neurological deficits in the donor site and painful neuroma can occur following surgery. The use of allogeneic nerve grafts is limited because of host immune rejection. As reported, tensile stress and tensile strain directly affect the quality of nerve regeneration after bridging nerve defects by poly(lactic-co-glycolic acid) conduit transplantation and autogenous nerve grafting for sciatic nerve injury. A new study published ...

Who benefits from vitamin D?

2013-08-13

Studying the expression of genes that are dependent on vitamin D makes it possible to identify individuals who will benefit from vitamin D supplementation, shows a University of Eastern Finland study published recently in PLoS One. Population-based studies have shown that vitamin D deficiency may increase the risk for chronic diseases and weaken the body's immune system. In the present study carried out at the University of Eastern Finland, Kuopio, the study participants were given a daily dose of either 40 or 80 micrograms of vitamin D, or a placebo, over a course of ...

Fuel cell innovation by Korean researchers

2013-08-13

Research team of Ulsan National Institute of Science and Technology (UNIST), Georgia Institute of Technology, and Dong-Eui University developed a novel cathode material which has outstanding performance and robust reliability even at the intermediate temperature range. This research was published in Scientific Reports on August 13. (Title: Highly Efficient and robust cathode materials for low-temperature solid fuel cells: PrBa0.5Sr0.5Co2-xFexO5+δ ) As high power density devices, fuel cells can convert chemical energy directly into electric power very efficiently ...

More than just a kinase: CDK6 in cancer

2013-08-13

Cancer in humans is frequently associated with unusually high amounts of one or more proteins responsible for controlling the rate at which cells divide. As an example, excessive amounts of the cyclin-dependent kinase CDK6 are often found in types of cancer such as lymphoma. Together with a number of collaborators within Vienna and beyond, Karoline Kollmann of the University of Veterinary Medicine, Vienna (Vetmeduni) has now shown that CDK6 is part of a multiprotein complex that stimulates the production of one of the so-called INK4 family members (confusingly termed ...

A hypnotic suggestion can generate true and automatic hallucinations

2013-08-13

A multidisciplinary group of researchers from Finland (University of Turku and University of Helsinki) and Sweden (University of Skövde) has now found evidence that hypnotic suggestion can modify processing of a targeted stimulus before it reaches consciousness. The experiments show that it is possible to hypnotically modulate even highly automatic features of perception, such as color experience. The results are presented in two articles published in PLoS ONE and International Journal of Clinical and Experimental Hypnosis. The Finnish part of the research is funded by ...

Highest winter losses in recent years for honey bees in Scotland

2013-08-13

A survey, run by Strathclyde academics on behalf of the Scottish Beekeepers' Association, indicated 31.3 per cent of managed honey bee colonies in Scotland failed to survive last winter – almost double the previous year's loss rate of 15.9 per cent. Dr Alison Gray and Magnus Peterson, of Strathclyde's Department of Mathematics and Statistics, warn the figures ought to be of major concern because bees play a pivotal role in crop pollination, agricultural yields and, therefore, food supply and prices. Last winter's figures represent 156 colonies lost during the winter ...